The Edema drugs in development market research report provides comprehensive information on the therapeutics under development for Edema, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Edema. Buy the report here.

Smarter leaders trust GlobalData

Report-cover

Data Insights Edema - Drugs In Development, 2023

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Edema and features dormant and discontinued products.

GlobalData tracks 12 drugs in development for Edema by 12 companies/universities/institutes. The top development phase for Edema is preclinical with four drugs in that stage. The Edema pipeline has 11 drugs in development by companies and one by universities/ institutes. Some of the companies in the Edema pipeline products market are: Karl-Franzens-Universitat Graz, Alteogen and Toa Eiyo.

The key targets in the Edema pipeline products market include Aquaporin 2 (ADH Water Channel or Collecting Duct Water Channel Protein or AQP2), A Disintegrin And Metalloproteinase With Thrombospondin Motifs 4 (ADMP1 or Aggrecanase 1 or ADAMTS4 or EC 3.4.24.82), and A Disintegrin And Metalloproteinase With Thrombospondin Motifs 5 (A Disintegrin And Metalloproteinase With Thrombospondin Motifs 11 or Aggrecanase 2 or ADMP2 or ADAMTS5 or EC 3.4.24.).

The key mechanisms of action in the Edema pipeline product include Toll Like Receptor 4 (hToll or CD284 or TLR4) Antagonist with one drug in Preclinical. The Edema pipeline products include seven routes of administration with the top ROA being Oral and five key molecule types in the Edema pipeline products market including Small Molecule, and Synthetic Peptide.

Edema overview

Edema is a condition where excess fluid accumulation is observed in the limbs bilaterally, appearing as as puffiness or swelling. This condition can be temporary, depending on the cause of the condition. There are various etiological factors: long-standing, low protein levels, pregnancy, chronic kidney disease (CKD), congestive heart failure (CHF), liver cirrhosis, venous insufficiency, and lung conditions like emphysema. Physical examination is the primary diagnostic method, where the swollen part is pressed by the thumb to see an indentation. Other tests include urine tests, chest X-ray, and ECG, based on the patient’s medical history of causal conditions. Fluid restriction is the primary treatment step, followed by supportive care as needed. A low-salt diet is a non-pharmacological intervention for patients with edema.

For a complete picture of Edema’s pipeline drug market, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.